FORMULATION AND EVALUATION OF PROPRANOLOL HYDROCHLORIDE ORAL DISINTEGRATING TABLETS

Background and purpose of the study: Propranolol hydro-chloride beta-adrenergic receptor antagonist utilized in the treatment of high blood pressure, atrial fibrillation, myocardial infarction, angina and migraine headaches. The pharmacokinetic parameters make Propranolol hydrochloride an appropriate candidate for oral disintegrating tablets. This work aims to develop orally disintegrating tablets for Propranolol hydrochloride and to evaluate their pre-compression, physicochemical properties and water absorption ratio, disintegrating time, wetting time, in-vitro dispersion, time, and in-vitro dissolution. Research rationale: To attain rapid disintegration, dissolution/absorption, and further improving the bioavailability of the drug. To resolve swallowing issues in geriatric, pediatric patients by rapid disintegration in saliva and to treat high blood pressure, angina, atrial fibrillation, myocardial infarction, migraine. Methods: Oral disintegrating tablets prepared by direct compression technique using super disintegrants like Crospovidone, Croscarmellose sodium, Sodium starch glycolate, and Pregelatinised starch in several concentrations. The prepared batches of tablets were evaluated for pre-compression parameters and weight variation, thickness, hardness, friability, drug content, wetting time, disintegrating time, in-vitro dispersion time and in-vitro dissolution. The physicochemical interaction between drug and excipients were investigated by Fourier transform infrared spectroscopy. Results: Among the prepared formulations, F5 (Crospovidone 6%) was optimized and shows the maximum cumulative amount of drug release 97.05% in 14 min and disintegration time is 14.25 sec. Spectroscopic studies showed no evidence of interaction between the drug and excipients. Conclusion: Propranolol orally disintegrating tablets were found to possess faster disintegration time and drug release.